We are committed to making a positive difference to global healthcare, thanks to our innovative ImplaVax® vaccination technology.
Better health outcomes
We have shown through in-vivo pre-clinical studies that our ImplaVax® technology can lead to the formation of highly efficacious and stable vaccines, generating a faster and higher total and specific antibody response than a traditional vaccine. We also expect that the use of ImplaVax® solid dose formulations will lead to increased uptake in vaccination, due to its strong potential for regimen sparing (as one dose can deliver both ‘Prime’ and ‘Booster’ inoculations) as the strong patient preference for needle-free vaccination. Combined with its benefits in terms of improved access, we strongly believe in our technology’s potential to improve health outcomes globally.
Improved access to medicine
During the 2019 Global Vaccine Summit, the World Health Organization delivered the message that lack of access is still the main factor hindering vaccine coverage. In 2019, for example, 19.7 million infants (60% of which were from only 10 developing world countries) did not receive a full DTP (diptheria, tetanus and pertussis) immunisation1.
Our ImplaVax® technology has the potential to help improve access to medicine thanks to the elimination of cold-chain requirements, which makes it particularly attractive for delivery in remote locations where vaccination uptake is particularly challenging. Medecins Sans Frontiers believes that the current vaccine cold chain requirement results in one in five children missing a life-saving vaccination2.
Furthermore, ImplaVax® solid dose formulations are designed to be administered with minimal training, and there is no need for additional diluents or water for reconstitution at point of care, eliminating more barriers to safe and easy vaccination programmes.
Reduced environmental footprint
We believe in the urgent need to fight climate change, which along with anti-microbial resistance (AMR) are two major challenges humanity faces in the near future. Our ImplaVax® technology has the potential to greatly reduce energy requirements associated with traditional vaccination, by reducing the number of doses needed and eliminating the need for cold chain requirements, which will drastically reduce energy use during the transport, storage and distribution phases.
Moreover, solid-dose vaccination reduces hazardous waste by eliminating the need to dispose of needles and syringes.